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Summary Osteosarcomas are a heterogeneous group of tumors with diverse anatomical, clin-
ical, and progressional characteristics. Parosteal osteosarcoma, or juxtacortical osteosarcoma,
is a rare form of osteosarcoma that develops at the bone surface, but has a better progno-
sis than other conventional osteosarcomas. We report the observation of a 22-year-old female
patient whose initial presentation was an enormous tumefaction of the knee that had been
progressing for 10 years. The biopsy concluded in PO of the lower third of the femur. Stag-
ing was negative. The tumor had reached an enormous size and required amputation of the
left lower extremity. A custom external prosthesis was manufactured to get her back to walk-
ing. Eight years after surgery, no local recurrence or metastasis has been detected. Parosteal
osteosarcoma is a rare form of osteosarcoma with very slow progression (in spite of the par-
ticularly dramatic presentation in our observation), with an excellent prognosis and very rare
metastasis.
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IntroductionParosteal osteosarcoma (PO), or juxtacortical osteosar-
coma (JCO), is a rare anatomical and clinical variant of
osteosarcoma, accounting for 4% of cases [1,2]. It progresses
slowly and has a good prognosis compared to conventional
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steosarcoma. The authors report an original observation
hat illustrates the low aggression of this tumor and discuss
ts anatomical and clinical features.
bservatione report the case of a female patient, born in 1978, con-
ulted in 1995 at the age of 17 years for a painless mass
n the right knee that had appeared at the age of 12 years
1990) and progressively increased in volume. The physi-
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by the tumor.
The histological analysis showed a malignant mesenchy-
matous proliferation, moderately cellular, made up of long,
linear and eosinophilic material, sometimes calciﬁed with noigure 1 The ﬁrst X-ray of the knee (at the age of 17 years):
ass of the lower one third of the femur, dense, relatively well
imited, attached to the metaphyseal cortex by a wide base.
al examination revealed a 2 cm mass at its largest above
he right popliteal fossa with knee ﬂexion moderately lim-
ted. The X-ray showed a mass in the lower third of the
emur that was dense, relatively well limited, attached
o the metaphyseal cortex by a wide base (Fig. 1). The
iopsy showed moderately cellular malignant tumor prolif-
ration, with slightly atypical and rarely mitotic fusiform
ells surrounded by osteoid trabeculae, providing a diagno-
is of JCO. Conservative treatment (wide resection of the
umor with knee prosthesis) preceded by a course of ﬁrst-
ine chemotherapy was planned at this stage. However, the
atient only received two cycles and then was lost to follow-
p. Two years later, in 1997, with continued progression
nd no response to the chemotherapy, amputation was pro-
osed but refused by the patient. She returned 3 years later
2000), at the age of 22, with a considerable increase in
umor volume. The physical examination showed a tumor
ass measuring 40 cm at its widest point, limiting all knee
ovement (Fig. 2). The plain X-ray showed voluminous lytic
nd condensing bone tumor, occupying the lower third of the
emur extending to the middle third with invasion of the soft
issues (Fig. 3).
Magnetic resonance imaging (MRI) showed a volu-
inous heterogeneous tumor, measuring approximately
5 cm× 25 cm, invading the soft tissues, the knee joint, the
pper third of the tibia and ﬁbula, as well as the medullary
avity, encompassing the vessels. This tumor was slightly
ypointense compared to the muscle and included areas
f hypointense signal on T1-weighted sequences, with no
nhancement after gadolinium injection. It was located
pproximately 10 cm from the center of the femoral head,
ith no skip metastases (Fig. 4).
The staging bone scintigraphy and thoracoabdominal CT
howed no secondary extension. The patient was treated by
mputation at the hip, performed on 20 May 2000, 10 years
fter the ﬁrst symptoms.
F
a
f
tigure 2 Enormous tumor mass measuring 40 cm at its widest
oint, limiting all knee movement.
The anatomopathological examination of the specimen
howed a 42 cm× 38 cm tumor of the knee and thigh. It
as located 7 cm from the limit of surgical resection. The
ut specimen presented a lobulated, whitish aspect with no
otable cartilaginous zones. The skeletal muscles, the knee
oint, and the upper end of the tibia and ﬁbula were invadedigure 3 X-ray 5 years later (age, 22 years): voluminous lytic
nd condensing bony tumor occupying the lower third of the
emur extending to the middle third and invading the soft
issues.
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Figure 4 MRI: heterogeneous tumor, slightly hypointense sig-
nal compared to muscle, with T1-weighted hyposignal areas,
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mwith no enhancement after gadolinium injection. The tumor
invaded the soft tissues of the knee and the medullary cavity
with no skip metastases.
osteoblastic cells in the periphery, corresponding to osteoid
(Fig. 5). The tumor cells were spindle-shaped, with little
eosinophil cytoplasm and a long or ovoid, hyperchromatic,
and moderately atypical nucleus. Mitoses were rare (Fig. 6).
There were no areas of dedifferentiation. We diagnosed
juxtacortical (parosteal) osteosarcoma with no dedifferen-
tiation areas, with healthy excision margins.
A walking prosthesis was prescribed that allowed the
patient to walk autonomously with no discomfort or assis-
tance. She was followed-up in outpatient consultation until
February 2008, with a last follow-up X-ray (of the thorax)
and scintigraphy (bone scintigraphy) showing neither recur-
rence nor metastasis 18 years after the ﬁrst symptoms.
Figure 5 Histology of parosteal osteosarcoma: moderately
cellular proliferation with long osteoid trabeculae with no
osteoblastic areas (magniﬁcation × 250).
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vigure 6 Greater magniﬁcation (× 400). Tumor cells are
pindle-shaped with a long or ovoid nucleus, hyperchromatic,
nd moderately atypical.
iscussion
O, or JCO, is a rare disease described for the ﬁrst time
y Gerschickter and Copeland in 1951 [3]. It is the most
requent form of bone surface osteosarcoma [1,2]. It is a
ell-differentiated, low-grade disease.
PO onset is on average 10 years later than conventional
steosarcoma [4,5]. Age at onset is between 15 and 40 years,
ith a mean of 28 years [2,6,7]. There seems to be a female
redominance, with a sex ratio of 1:3. Our patient was a
2-year-old girl at the time of diagnosis. PO usually presents
ith a globular, juxta-articular mass that is fairly well lim-
ted, hard in consistency, slow-growing, generally painless,
ut it can cause functional discomfort, limiting joint move-
ent in one third of cases [6,7]. The painless quality of the
isease explains the delay in diagnosis. In our observation,
he tumor evolved progressively and slowly for 10 years,
eaching an impressive size.
The most frequent seat is the distal end of the femur,
here the tumor arises typically on the posterior side. This
ocation is followed by the proximal end of the tibia, then
arely by the proximal end of the femur, humerus, and radius
1,5]. PO cases reaching the carpal or tarsal bones and the
at bones have been described [7].
The radiology aspect is typical. PO presents as a
adiopaque, metaphyseal mass developing on the exter-
al side of the cortex, extending toward the soft tissues.
his mass is dense and homogeneous, with polycyclic or
rchiform contours. At an early stage, there is a radio-
ransparent groove that separates the tumor from the bone
ortex except at the base of the implantation. When it is
resent, this sign has a high diagnostic value. It disappears
n voluminous tumors. According to Edeiken-Monroe et al.,
his clear ring corresponds to the periosteum between the
umor and the bone cortex [7,8]. Periosteal reaction, fre-
uent in conventional osteosarcoma, is absent in PO. In
ur case, the ﬁrst X-ray showed a dense, quite well-limited
ass, attached to the metaphyseal cortex by a wide base.
he clear space between the tumor and the cortex is not
ery sharp on the X-ray image.
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CT provides a better image of the radiotransparent
roove, clariﬁes the tumor’s implantation base, and demon-
trates any intramedullary extension or satellite lesions. MRI
s the choice examination to detect intramedullary invasion
nd elucidate the tumor’s position in relation to vascular
nd nerve structures [7,9]. In our case, MRI demonstrated a
oluminous heterogeneous tumor invading the soft tissues,
he knee joint, the upper third of the tibia and ﬁbula, and
he medullary cavity, including the vessels.
The macroscopic aspect is typical. The tumor presents
s a voluminous, exophytic, ossiﬁed mass, with well-limited
ontours, attached to the bone by a wide base, pushing
he adjacent structures back. The cut specimen has a het-
rogeneous aspect, showing some ﬁbrous zones and some
artilaginous zones. Intramedullary extension is present in
5% of cases and should be meticulously searched for in
ultiple samples. The existence of areas of soft and ﬂeshy
onsistency suggest dedifferentiation [1]. In our case, these
ones of soft and ﬂeshy consistency were not found.
Histologically, the tumor comprises parallel osteoid tra-
eculae with or without a peripheral osteoblastic area.
hese trabeculae are separated by cellular proliferation,
ade up of spindle-shaped cells presenting minimal atypia
nd a low level of mitotic activity [1,2].
In 50% of cases, the tumor presents areas of cartilaginous
ifferentiation in the form of nodules or a cap in the surface
1]. In the case reported here in, we found no cartilaginous
odules. Three histological grades are distinguished: grades
and II, corresponding to the conventional form, with a low
evel of malignity. Grade III, corresponding to the dediffer-
ntiated form with manifest atypia and mitoses, has a high
evel of malignity.
Dedifferentiation is observed in 15% of cases. It is present
t diagnosis or most often at recurrence. This dediffer-
ntiation can manifest as osteosarcoma, ﬁbrosarcoma, or
alignant histiocytoma [1]. In the case reported herein, no
reas of dedifferentiation were found and the tumor was
ow grade (conventional PO).
The differential diagnosis is made essentially with benign
esions such as osteoma, osteochondroma, ossifying myosi-
is, and periosteum desmoid. Clinical and radiological data
ontribute enormously to the diagnosis. Histologically, these
esions do not develop in a sarcomatous stroma and the cells
re regular with no atypia or hyperchromatism. The dif-
erential diagnosis is also made with low-grade periosteal
steosarcoma and intramedullary osteosarcoma. The radio-
ogical presentation is different and there is no clear space
etween the tumor and the cortex. From a macroscopic
iewpoint, there is a topographical difference between the
umor and the bone structures [10].
The recommended treatment is surgery consisting of
ide resection of the tumor in a single piece. Accord-
ng to Enneking, resection can be intracapsular, marginal,
ide, or radical. Amputation is reserved for cases in which
ide resection cannot be performed, as in our patient,
r when the tumor is dedifferentiated or recurrent. Adju-
ant chemotherapy can be effective in the dedifferentiated
orms [11]. Our patient received a course of primary
hemotherapy but did not respond. The prognosis of PO is
ood if the patient is properly treated. Overall survival at
years is of the order of 91% [1]. The risk of local recur-
[E. Ben Brahim et al.
ence depends on the quality of the excision. It is 50% if
he resection is marginal, passing in a peritumoral reactive
one [12,13]. If resection is total, recurrence is exceptional.
are cases of tumor recurrence after a long period have been
eported: 15 years in Okada and Swee’s series and 20 years in
he case reported by Lau et al. [4,14]. Metastases are seen in
8% of cases. They are generally associated with dedifferen-
iated or recurrent forms or those with medullary invasion.
he most frequent site is the lungs, rarely the abdomen and
entral nervous system, and exceptionally the myocardium
14]. In our patient, during a slow progression over 10 years
efore intervention, followed-up for 8 years after amputa-
ion, no recurrence or metastasis has been observed.
onclusion
O is a low-grade malignant bone tumor characterized by
ts insidious progress and good prognosis. It rarely leads
o metastasis. Its treatment is essentially surgical. Areas
f dedifferentiation are the main factor indicating poor
rognosis. Our observation illustrates that this tumor is not
ggressive, with no metastasis after 18 years of progression.
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